EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Claudin-18 expression is associated with poorer overall survival in colorectal cancer

Aya Y Al-Kabariti, Manal A Abbas iD, Maxim Alashhab, Sneha Smarakan, Maher A Sughayer iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0360740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Aya Y Al-Kabariti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Claudins, Colorectal Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Ahliya Amman Uuiversity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin 18, a tight junction protein, has emerged as a therapeutic target in various gastrointestinal cancers, notably gastric adenocarcinoma. However, its prevalence and clinicopathological significance in colorectal cancer (CRC) remain incompletely understood. In the current single-center, retrospective, immunohistochemical study, the prevalence and prognostic value of Claudin-18 was investigated in CRC. Claudin-18 expression was detected in 15.9% (17/107) of CRC cases, with negative/weak expression in 84.1% (90/107). No significant associations were observed between Claudin-18 expression and age, sex, tumor site, T stage, lymph node status, distant metastasis, TNM stage, histological subtype, or lymphovascular invasion (all p > 0.05). No significant associations were identified between Claudin-18 expression and age, sex, tumor location, histological subtype, or TNM stage. Furthermore, Claudin-18 expression independently predicted survival outcomes in CRC where Kaplan–Meier analysis demonstrated significantly worse overall survival (OS) in patients with strong/moderate Claudin-18 expression compared with Claudin-18 -negative/weak expression (log rank test, p = 0.024). Mean OS was markedly longer in Claudin-18 -negative/weak expression group (121.0 vs.76.6 months). Progression-free survival (PFS) analysis demonstrated a trend toward poorer outcomes among patients with increased Claudin-18 expression; however, the difference did not reach statistical significance (log-rank test, p = 0.066). Event-free survival (EFS) was also significantly reduced in patients with strong/moderate Claudin-18 expression (log-rank test, p = 0.022). Mean EFS was markedly longer in CLDN18 negative/weak expression (93.1 vs. 31.1 months). Multivariable binary logistic regression showed that the overall model was statistically significant (χ2(7) = 22.657, p = 0.002). However, none of the evaluated variables—including gender, age, lymphovascular invasion, tumor laterality, TNM stage, MSI status, histological type, and Claudin-18 expression—was independently associated with the outcome (all p > .05). Claudin-18 expression was not a significant predictor in the adjusted model (p = 0.931; OR = 0.63). In conclusion, despite its low prevalence in the current cohort, Claudin-18 expression was associated with poorer overall survival; however, its independent prognostic value was not established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClaudinsColorectal NeoplasmsHumansFemaleMalePrognosisMiddle AgedAgedRetrospective StudiesNeoplasm StagingBiomarkers, TumorKaplan-Meier EstimateAdultAged, 80 and over

Substanzen

ClaudinsCLDN18 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
  • Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan.
  • Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Institute of Cancer Therapeutics, Faculty of Health and Social Care, University of Bradford, West Yorkshire, United Kingdom.
  • Faculty of Medicine, The University of Jordan, Amman, Jordan.

ORCID-Profile: Manal A Abbas, Maher A Sughayer

Förderung

  • Al-Ahliya Amman Uuiversity

Zitieren

APA

Al-Kabariti, A. Y., Abbas, M. A., Alashhab, M., Smarakan, S., & Sughayer, M. A. (2026). Claudin-18 expression is associated with poorer overall survival in colorectal cancer. PLOS One. https://doi.org/10.1371/journal.pone.0360740

Vancouver

Al-Kabariti AY, Abbas MA, Alashhab M, Smarakan S, Sughayer MA. Claudin-18 expression is associated with poorer overall survival in colorectal cancer. PLOS One. 2026. doi:10.1371/journal.pone.0360740

BibTeX
@article{AlKabariti2026,
  author = {Al-Kabariti, Aya Y and Abbas, Manal A and Alashhab, Maxim and Smarakan, Sneha and Sughayer, Maher A},
  title = {Claudin-18 expression is associated with poorer overall survival in colorectal cancer},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0360740}
}
Kostenlos starten →